NanoViricides announced that its antiviral drug NV-387 has received Orphan Drug Designation from the US FDA for treating measles. This designation offers benefits like tax credits, fee exemptions, and up to seven years of market exclusivity, potentially speeding regulatory approval. NV-387 is notable for strong activity against lethal measles in preclinical models and is also being considered for a Rare Pediatric Disease Drug designation, which could further accelerate FDA review. The drug has shown promise against other viruses including RSV, COVID-19, and influenza.
CBAK Energy Technology showcased its innovative lithium-ion and sodium-ion cylindrical batteries designed for Southeast Asia's electric two- and three-wheelers at Autotech & Accessories 2026. Their batteries feature long life, high reliability, and s...
WeRide and Renault Group continue their partnership by operating the autonomous Robobus shuttle service at the Roland-Garros tennis tournament for the third consecutive year. The service runs a 2.8 km route connecting key points around the stadium, o...
Municipality Finance Plc has issued a $1 billion benchmark bond under its Medium Term Note (MTN) programme, with a fixed interest rate of 4.25% per annum and maturity set for May 27, 2031. This bond is part of MuniFin's EUR 50 billion debt issuance p...
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
SpaceX's upcoming IPO may cause forced ETF buying of $22-$27 billion as Nasdaq changes rules to fast-track the company's index inclusion. The Nasdaq 100 now allows new companies to join within 15 days if their market cap ranks in the top 40, removing...
